| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.093 | 0.03 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.03 |